Information Provided By:
Fly News Breaks for April 29, 2016
AMGN
Apr 29, 2016 | 05:59 EDT
Piper Jaffray analyst Joshua Schimmer says Amgen reported another impressive quarter in Q1. The company reported strong numbers for its growth franchise and executed effectively on its switch from Epogen to Aranesp and Neulasta to the ONpro auto injector, Schimmer tells investors in a research note. He raised his price target for the shares to $193 from $191 and reiterates an Overweight rating on the name.
News For AMGN From the Last 2 Days
There are no results for your query AMGN